The adiponectin agonist AdipoRon accelerates osteoporosis development in two different models and modulates adipocyte differentiation
Bone · 2025
DOI: 10.1016/j.bone.2025.117628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2025. Verfasst von Julia Halper und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lorraine, CNRS, IMoPA, Nancy, France; Arthritis R&D, Neuilly-sur-Seine, France. Hauptthemen laut MEDLINE: Adipocytes, Adiponectin, Osteoporosis, Cell Differentiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency, La Région Grand Est, Fondation de l'Avenir pour la Recherche Médicale Appliquée.
Abstract (Originalsprache)
Osteoporosis is an increasing concern in the aging population worldwide, culminating in increased economic concerns and diminished quality of life. Similarly, disturbances of lipid metabolism and adipocytes accumulate more and more in western societies and need solutions. Adipocytes have recently attracted much interest in relation to their endocrine products, one of which is adiponectin, normally associated with beneficial effects on cardiovascular health, inflammation, and cancer. In this study, we have investigated the effect of AdipoRon, an adiponectin receptor agonist with reported anti-osteoclastic properties, on the development of osteoporosis in two different preclinical models. Contrasting to our initial hypothesis, AdipoRon treatment accelerated metabolic changes and bone loss in both models. However, AdipoRon rescued bone marrow adipocytes presence induced by glucocorticoids. Investigations on adipocyte differentiation revealed that AdipoRon potently changes adipocyte identity, by exerting opposite effects on adipocyte-gene induction depending on the time point and duration of stimulation. In conclusion, adipocyte-derived Adiponectin deserves further investigation as an autocrine mediator in musculoskeletal research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Lorraine, CNRS, IMoPA, Nancy, France; Arthritis R&D, Neuilly-sur-Seine, France.
- Université Côte d'Azur, CNRS, IPMC, France.
- Center for Integrative Genomics, Genopode, Lausanne Faculty of Biology and Medicine, Lausanne, Switzerland; Faculty Unit of Toxicology, University Center of Legal Medicine, Faculty of Biology and Medicine, Lausanne Univ…
- Center for Integrative Genomics, Genopode, Lausanne Faculty of Biology and Medicine, Lausanne, Switzerland.
- Université Côte d'Azur, CNRS, LP2M, France.
- Université de Lorraine, CNRS, IMoPA, Nancy, France.
Förderung
- French National Research Agency
- La Région Grand Est
- Fondation de l'Avenir pour la Recherche Médicale Appliquée
- University of Lorraine
- Fund for Scientific Research
- Canton of Vaud General Directorate of Public Health
Zitieren
APA
Halper, J., Nicolas, S., Gilardi, F., Winkler, C., Materozzi, M., Schiffrin, M., Jouzeau, J. Y., Blin-Wakkach, C., Desvergne, B., Chabry, J., Pisani, D. F., & Moulin, D. (2025). The adiponectin agonist AdipoRon accelerates osteoporosis development in two different models and modulates adipocyte differentiation. Bone. https://doi.org/10.1016/j.bone.2025.117628
Vancouver
Halper J, Nicolas S, Gilardi F, Winkler C, Materozzi M, Schiffrin M, et al. The adiponectin agonist AdipoRon accelerates osteoporosis development in two different models and modulates adipocyte differentiation. Bone. 2025. doi:10.1016/j.bone.2025.117628
BibTeX
@article{Halper2025,
author = {Halper, Julia and Nicolas, Sarah and Gilardi, Federica and Winkler, Carine and Materozzi, Maria and Schiffrin, Mariano and Jouzeau, Jean-Yves and Blin-Wakkach, Claudine and Desvergne, Beatrice and Chabry, Joelle and Pisani, Didier F and Moulin, David},
title = {The adiponectin agonist AdipoRon accelerates osteoporosis development in two different models and modulates adipocyte differentiation},
journal = {Bone},
year = {2025},
doi = {10.1016/j.bone.2025.117628}
}
EUVIMED